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Introduction
Febuxostat is a unique xanthine oxidase inhibitor that was approved for the prevention of 
gout in the United States in 2009.1 Unlike allopurinol, febuxostat is not a nucleoside 
analogue and has a higher specificity for xanthine oxidase. Although this drug has not been 
on the market for a long time, febuxostat may be safer than allopurinol.2,3 Importantly, 
febuxostat appears to be safer than allopurinol, which has been linked to many instances of 
severe hypersensitivity reactions, including skin rash with eosinophilia and systemic 
manifestations (DRESS syndrome), Stevens Johnson syndrome, acute nephritis, acute icteric 
hepatitis and acute liver failure.3,4 While febuxostat is not infrequently associated with 
serum enzyme elevations during treatment, it has yet to be linked to cases of clinically 
apparent acute liver injury.3, 4 We report a case of acute liver injury with jaundice due to 
febuxostat and which was identified in a prospective study of drug-induced liver injury in 
the United States.5
Case
A 34 year old man with obesity and severe gout developed fatigue, nausea, and abdominal 
pain followed by dark urine, jaundice and itching 2 months after adding febuxostat (40 mg 
daily) to his regular regimen of colchicine (1.2 mg) and allopurinol (300 mg) per day. He 
had no history of liver disease, alcohol use or risk factors for viral hepatitis. His other 
medical problems included obesity, hypertension, dyslipidemia, sleep apnea, depression and 
inactive sarcoidosis. Other medications included simvastatin, lisinopril, hydrochlorothiazide, 
ranitidine, amitriptyline and acetaminophen with codeine (1-2 tablets daily). He denied use 
of herbals or over-the-counter products.
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At presentation, physical examination showed severe obesity (BMI 63.3 kg/m2) and 
jaundice, but no fever, rash or signs of chronic liver disease. Serum bilirubin was 8.3 mg/dL, 
alkaline phosphatase (Alk P) 201 U/L, alanine aminotransferase (ALT) 148 U/L and 
amylase 779 U/L. Complete blood count was normal with 5% eosinophils (normal 1-4%); 
INR was 1.09. Tests for hepatitis A, B, C and E were negative as were antinuclear and 
smooth muscle antibodies. Abdominal ultrasound and computerized tomography showed 
gallstones but no evidence of biliary obstruction. An ERCP confirmed these findings. Due to 
elevated bilirubin and acute pancreatitis in the context of extreme obesity, a decision to 
perform ERCP rather than a MRCP was made. At that time, allopurinol, hydrochlorothiazide 
and lisinopril were stopped, while febuxostat was continued. Laboratory results improved 
minimally (Figure 1). A liver biopsy showed changes suggestive of intrahepatic cholestasis 
with mild inflammation and necrosis but without bile duct injury or fibrosis (Figure 2). Forty 
days after presentation, febuxostat was finally discontinued and was promptly associated 
with symptom resolution and normalization of liver tests. Allopurinol, lisinopril and 
hydrochlorothiazide were restarted and liver tests remained normal at the 6 month follow up 
visit per protocol.
Discussion
The clinical course, serum enzyme elevations, liver histology and response to stopping 
treatment were most consistent with the diagnosis of febuxostat-induced acute liver injury. 
Other common causes of acute liver injury were excluded and other potentially hepatotoxic 
drugs were restarted without recurrence of injury. Adjudication by 3 reviewers in the Drug-
Induced Liver Network scored the case as “highly likely” due to febuxostat.5 The latency of 
2 months, cholestatic pattern of serum enzyme elevations and liver histology of cholestatic 
hepatitis were typical of drug-induced liver injury, but somewhat atypical of allopurinol 
hepatotoxicity, which usually causes hepatocellular injury features of hypersensitivity 
(fever, rash, eosinophilia) and acute hepatitis with eosinophils and granulomas on liver 
biopsy. While febuxostat was not linked to instances of clinically apparent liver injury in 
pre-licensure studies, it was associated with serum enzyme elevations.3 In this case, 
febuxostat was associated with jaundice probably because of its continuation after onset of 
liver injury. Thus, febuxostat is a rare but convincing cause of clinically apparent liver 
injury presenting with a cholestatic pattern of liver test abnormalities without evidence of 
hypersensitivity or autoimmune features and with rapid improvement once therapy is 
discontinued.
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Figure 1. 
Schematic representation of exposure, dechallenge, clinical events with trends of serum liver 
biochemistries during the clinical course and follow up.
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Figure 2. 
Light microscopy with magnification of liver histology with stains. Panel A. Hematoxylin 
and Eosin (H&E) – 20×: At low power, the biopsy shows hepatocytes with significant 
ballooning injury. Panel B. H&E – 40×: At high power, the biopsy shows marked cellular 
and canalicular cholestasis, as well as ballooned hepatocytes. Panel C. CK7 – 20×: The 
cytokeratin 7 immunohistochemical stain shows mild ductular reaction.
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